Growth in Indian Pharma Market Reflected in Expected Record Numbers for CPhI, P-MEC, ICSE and BioPh India 2010 Events

By Ubm Live, PRNE
Tuesday, November 9, 2010

Mumbai All Set for Biggest Ever Indian Pharma Event

AMSTERDAM, November 10, 2010 - Reflecting the rapid growth in the Indian Pharma market, leading events
organiser UBM Live today announced that it expects to see a record number of
attendees at its upcoming trade events, CPhI India for pharmaceutical
ingredients and intermediates, and co-located events, P-MEC for equipment and
machinery; ICSE for contract services and packaging; and BioPh for the
biopharma sector. Attendee numbers in 2009 hit 26,303, a number that included
almost 2,500 international. Visitors came from 86 countries, reflecting the
importance of India not only for domestic companies but as a market
presenting significant opportunities on the global stage.

For the 2010 events, which take place from December 1-3 at the Bombay
Exhibition Centre in Mumbai, UBM expects to see record attendance levels,
having seen increased registration and international exhibitor numbers. This
prediction is supported by the fact that this year's exhibitor stands sold
out in record time, prompting the addition of two new exhibit halls, which
also sold out rapidly. For 2010, the number of exhibitors is expected to top

Indian pharma companies have successfully established themselves in the
global market, especially in outsourcing and generics and are steadily
acquiring western pharma companies. India is at the leading edge (of the
pharma market, which grew domestically by 13% in 2009(1), twice that of the
global market growth rate. This number is expected to continue its upward
trend partly as a result of a new patent structure in India, which will scale
up to enable 30 approvals annually, with an average approval time frame of
just two years(2), compared to 3.4 years in the US for a drug patent and 4.4
years for a bio-tech patent.

"While CPhI India is very well attended by visitors from the local
markets and industries, its appeal is global, and the event attracts a great
deal of interest from visitors from outside the pan-Asia region, who interact
with domestic and international exhibitors on a wide variety of issues,"
commented Annemieke Timmers, CPhI India Brand Director. "As one of the
foremost international pharmaceutical events in this increasingly important
and vibrant market, CPhI India provides visitors with not only with solid
networking opportunities, but also scope to broaden their knowledge base
through a series of keynote speakers and interactive workshops that
encompasses the newest market trends, technologies, products and
opportunities. Constantly developing a portfolio of events so that they
continue to drive discussion across their respective audiences and seek to
tackle the hot button topics are key ongoing objectives for the event. To
reinforce this point, the CPhI India Conference series 2010, which runs
alongside the main events, comprises of twelve conference modules covering
the most relevant topics in the Indian marketplace, including: drug
discovery, biosimilars, nanotechnology, vaccine, oncology, stem cells,
generics, and machinery."

A main focus point of CPhI India and its co-located shows is providing
emphasis that reflects the prevalent trends in the market. This is perfectly
illustrated this year with the inclusion of the ICSE Pavilion, which provides
a core focus on outsourcing and contract services - a sector growing at 43%
annually in India, three times the global rate(3). With a highly skilled
workforce, India is becoming one of the most desirable markets to drive
business forwards. In addition to manufacturing and research, the other main
contract services provided in India are packaging, clinical trials,
laboratory services, drug discovery and marketing services. This is alongside
the overall growth of the India Pharma market is the associated machinery and
equipment market, which is growing on average at 15-20% per year(4). As a
result of these trends, P-MEC has seen increasing levels of interest over the
last few years. P-MEC provides attendees with a forum to explore the newest
advances in equipment and source high-quality machinery and equipment at
competitive prices. Showing the growing relevance of this show, P-MEC
attendance grew from 1352 to 1633 in 2009, an increase of 21%.

Further information about CPhI India and its co-located events can be
found online at, and

    Notes for Editors:
    -- UBM Live operates market-leading global exhibition brands and their
       complementary media products.
    -- The CPhI pharmaceutical ingredients and related sector exhibitions
       currently number over 15 highly-regarded annual events. The portfolio
       also includes Informex (specialty chemicals), Food Ingredients, HBA
       (health & beauty industry) and Sea Trade (cruise industry).
    -- Worldwide locations for its events include China, India, Japan, North
       America, Brazil, Africa and Europe. More than 330,000 business
       professionals and marketers visit UBM exhibitions each year. The
       exhibitions portfolio is managed from Holland. UBM Live has
       approximately 1,200 employees in the UK, US, Asia and Europe. See

(1) The Pharmerging Future. IMS

(2) India Pharma 2015: Unlocking the Potential of the Indian
Pharmaceuticals Market. McKinsey&Company

(3) Aashruti Kak: Regulating Outsourcing

(4) Pharmaceutical Machinery: Indian Market.

Media Enquiries: Impress PR: Global (excl. North America): Richard Kerns, richard at, +44-161-728-5880, or North America: Erin Hatzi, erin at, +1-503-928-7870; or Company Enquiries: UBM Live: Rob Sahi (CPhI), +31-20-40-99-5561, or Ian O'Malley (ICSE, P-MEC, BioPh), +31-20-40-99-5526

will not be displayed